Jobs
-
Teva UK has announced the launch of a generic CFC-free salmeterol metered dose inhaler in the UK; the product is a suspension pMDI that delivers 25 mcg per actuation. The UK granted marketing authorization for… Read more . . .
-
Gerresheimer Regensburg GmbH is looking to fill the following challenging position at its Wackersdorf site: Project Manager (m/f) Your duties: • You will manage and coordinate your project team – from the point when an… Read more . . .
-
The client is a privately held specialty biotech company focused on developing combination therapies in the respiratory, pulmonary, and asthma areas. This position will involve set up and operation of an MDI processing laboratory. The… Read more . . .
-
Alexza Pharmaceuticals and Spanish pharmaceutical company Grupo Ferrer International have formed a partnership to register, distribute, and promote the Adasuve Staccato loxapine inhaler for the treatment of agitation in patients with schizophrenia or bipolar disorder… Read more . . .
-
King’s College London will be the site of Phase 2 trials of Lightlake Therapeutics’s opioid antagonist-based nasal spray treatment for bulimia nervosa, the company has announced. Lightlake currently has Phase 2 trials underway in Finland… Read more . . .
-
Inhaler manufacturers who have been purchasing acrylonitrile butadiene styrene (ABS) for inhaler housings from either BASF or Ineos will now have a new supplier: Styrolution. Ineos’s Lustran, Novodur, and Absolac brands and BASF’s Terluran brand… Read more . . .
-
Swiss vaccine developer Mymetics Corporation has reclaimed an intranasal influenza vaccine that it had licensed to Solvay prior to Solvay’s acquisition by Abbott Laboratories. Solvay had conducted a Phase 1 trial that found the vaccine… Read more . . .
-
Job Title: DPI Analytical Senior Scientist Organization Unit: R&D – CMC – Strategic Product Enhancement The client, a global multinational company headquartered in Italy, is seeking an enthusiastic and self-motivated individual who would be interested… Read more . . .
-
Novartis Pharmaceuticals Canada has announced that the Québec provincial government will now provide reimbursement for the TOBI Podhaler tobramycin DPI for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis patients.The company cites data from… Read more . . .
-
Only about a month after entering the nasal delivery device market, Bespak has announced a second contract for development of an intranasal device. The company says that “a major global manufacturer of generic medicines” has… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA